168 related articles for article (PubMed ID: 23927436)
1. Probing the effects of hapten stability on cocaine vaccine immunogenicity.
Cai X; Whitfield T; Moreno AY; Grant Y; Hixon MS; Koob GF; Janda KD
Mol Pharm; 2013 Nov; 10(11):4176-84. PubMed ID: 23927436
[TBL] [Abstract][Full Text] [Related]
2. Hapten optimization for cocaine vaccine with improved cocaine recognition.
Ramakrishnan M; Kinsey BM; Singh RA; Kosten TR; Orson FM
Chem Biol Drug Des; 2014 Sep; 84(3):354-63. PubMed ID: 24803171
[TBL] [Abstract][Full Text] [Related]
3. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
Wenthur CJ; Cai X; Ellis BA; Janda KD
Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
[TBL] [Abstract][Full Text] [Related]
4. Flagellin as carrier and adjuvant in cocaine vaccine development.
Lockner JW; Eubanks LM; Choi JL; Lively JM; Schlosburg JE; Collins KC; Globisch D; Rosenfeld-Gunn RJ; Wilson IA; Janda KD
Mol Pharm; 2015 Feb; 12(2):653-62. PubMed ID: 25531528
[TBL] [Abstract][Full Text] [Related]
5. Modulating cocaine vaccine potency through hapten fluorination.
Cai X; Tsuchikama K; Janda KD
J Am Chem Soc; 2013 Feb; 135(8):2971-4. PubMed ID: 23398531
[TBL] [Abstract][Full Text] [Related]
6. Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.
Arutla V; Leal J; Liu X; Sokalingam S; Raleigh M; Adaralegbe A; Liu L; Pentel PR; Hecht SM; Chang Y
ACS Comb Sci; 2017 May; 19(5):286-298. PubMed ID: 28383252
[TBL] [Abstract][Full Text] [Related]
7. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.
Pryde DC; Jones LH; Gervais DP; Stead DR; Blakemore DC; Selby MD; Brown AD; Coe JW; Badland M; Beal DM; Glen R; Wharton Y; Miller GJ; White P; Zhang N; Benoit M; Robertson K; Merson JR; Davis HL; McCluskie MJ
PLoS One; 2013; 8(10):e76557. PubMed ID: 24098532
[TBL] [Abstract][Full Text] [Related]
8. Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.
Cai X; Whitfield T; Hixon MS; Grant Y; Koob GF; Janda KD
J Med Chem; 2013 May; 56(9):3701-9. PubMed ID: 23627877
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of a deuterated 6-AmHap internal standard for the determination of hapten density in a heroin vaccine drug product.
Makarova M; Barrientos RC; Torres OB; Matyas GR; Jacobson AE; Sulima A; Rice KC
J Labelled Comp Radiopharm; 2020 Nov; 63(13):564-571. PubMed ID: 32876947
[TBL] [Abstract][Full Text] [Related]
10. Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines.
Torres OB; Jalah R; Rice KC; Li F; Antoline JF; Iyer MR; Jacobson AE; Boutaghou MN; Alving CR; Matyas GR
Anal Bioanal Chem; 2014 Sep; 406(24):5927-37. PubMed ID: 25084736
[TBL] [Abstract][Full Text] [Related]
11. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.
Taylor JJ; Laudenbach M; Tucker AM; Jenkins MK; Pravetoni M
J Immunol Methods; 2014 Mar; 405():74-86. PubMed ID: 24462800
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and immunological effects of heroin vaccines.
Li F; Cheng K; Antoline JF; Iyer MR; Matyas GR; Torres OB; Jalah R; Beck Z; Alving CR; Parrish DA; Deschamps JR; Jacobson AE; Rice KC
Org Biomol Chem; 2014 Oct; 12(37):7211-32. PubMed ID: 24995943
[TBL] [Abstract][Full Text] [Related]
13. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse.
Collins KC; Janda KD
Bioconjug Chem; 2014 Mar; 25(3):593-600. PubMed ID: 24521489
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of a Heroin Vaccine through Hapten Deuteration.
Belz TF; Bremer PT; Zhou B; Ellis B; Eubanks LM; Janda KD
J Am Chem Soc; 2020 Aug; 142(31):13294-13298. PubMed ID: 32700530
[TBL] [Abstract][Full Text] [Related]
15. Anti-cocaine vaccines: antibody protection against relapse.
Kantak KM
Expert Opin Pharmacother; 2003 Feb; 4(2):213-8. PubMed ID: 12562311
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
[TBL] [Abstract][Full Text] [Related]
17. Impact of distinct chemical structures for the development of a methamphetamine vaccine.
Moreno AY; Mayorov AV; Janda KD
J Am Chem Soc; 2011 May; 133(17):6587-95. PubMed ID: 21473576
[TBL] [Abstract][Full Text] [Related]
18. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine Vaccines: Improvement through Hapten Design.
Collins KC; Schlosburg JE; Bremer PT; Janda KD
J Med Chem; 2016 Apr; 59(8):3878-85. PubMed ID: 27054372
[TBL] [Abstract][Full Text] [Related]
20. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects.
Wee S; Hicks MJ; De BP; Rosenberg JB; Moreno AY; Kaminsky SM; Janda KD; Crystal RG; Koob GF
Neuropsychopharmacology; 2012 Apr; 37(5):1083-91. PubMed ID: 21918504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
